Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Regulatory News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Key patent grants expand exosome IP portfolio

16 Jul 2019 07:00

RNS Number : 6496F
ReNeuron Group plc
16 July 2019
 

 

 

16 July 2019

AIM: RENE

 

 

ReNeuron Group plc

("ReNeuron" or the "Company")

 

Key patent grants expand exosome IP portfolio

 

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that it has expanded its intellectual property estate via the grant of a number of key patents covering its exosome technology platform.

 

New patents have recently issued covering ReNeuron's neural stem cell-derived exosomes and their methods of production. Patents granted in China (CN 104321062 B and CN 104703609 B), Korea (KR 10-1993027), Japan (JP 6450673) and Europe (EP2833893 and EP2877187) include claims to: (i) a method of producing exosomes derived from differentiated stem cells; (ii) methods of production; and (iii) composition of matter for exosomes derived from the Company's CTX neural stem cells.

 

A further patent has issued in Japan (JP 6491661) with claims including use of a neural stem cell exosome in the treatment of glioma (brain cancer).

 

ReNeuron is targeting its exosome technology programme towards value-generating business partnerships in which its exosomes may be exploited as a novel vector for delivering third party biological drugs.

 

Following these patent grants, ReNeuron's patent estate consists of over 40 patents worldwide covering its cell-based therapies and exosome technology.

 

Olav Hellebø, Chief Executive Officer of ReNeuron, commented: 

"We are pleased to have received these recent patent grants relating to our exosome technology platform. We expect to build this patent estate further in the near future. The recent and expected grants will stand us in good stead as we seek valuable collaboration deals to exploit ReNeuron's exosome platform as a novel system for delivering advanced therapeutics such as gene therapies."

ENDS

 

ENQUIRIES:

 

ReNeuron

 +44 (0)20 3819 8400

Olav Hellebø, Chief Executive Officer

Michael Hunt, Chief Financial Officer

 

Buchanan (UK)

 

+44 (0) 20 7466 5000

Mark Court, Sophie Wills, Tilly Abraham

 

Argot Partners (US)

Stephanie Marks, Claudia Styslinger

 

Stifel Nicolaus Europe Limited

+1 212 600 1902

 

 +44 (0) 20 7710 7600

Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker)

 

N+1 Singer

 

+44 (0) 20 7496 3000

Aubrey Powell, James Moat, Iqra Amin

(Joint Broker)

 

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa, and for disability as a result of stroke. ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCSFLSIMFUSEEW
Date   Source Headline
20th Mar 20243:43 pmRNSAppointment of Administrators
20th Mar 202412:30 pmRNSIntention to Appoint Administrators
1st Mar 20247:00 amRNSBlock Listing Review & Total Voting Rights
5th Feb 20242:30 pmRNSCorporate update and suspension of trading on AIM
5th Feb 20242:30 pmRNSSuspension - ReNeuron Group plc
27th Nov 20238:53 amEQSEdison issues update on ReNeuron Group (RENE): H124 results reaffirm focus on CustomEX™
8th Nov 20237:01 amRNSInterim Results for the six months ended 30 Sept
8th Nov 20237:00 amRNSReNeuron presents in vivo data at Cell 2023
4th Sep 20237:00 amRNSR&D Update
1st Sep 20237:00 amRNSBlock Listing Review & Total Voting Rights
29th Aug 20237:00 amRNSDirector declaration
22nd Aug 202310:34 amRNSResult of AGM
24th Jul 20235:20 pmRNSNotice of AGM
12th Jul 202311:57 amRNSShare Purchase by Chief Financial Officer
16th Jun 20235:12 pmRNSShare Purchase by Senior Independent NED
16th Jun 20232:26 pmRNSShare Purchase by Executive Chairman
16th Jun 20237:00 amRNSPosting of Annual Report & Accounts
5th Jun 20234:30 pmRNSHolding(s) in Company
25th May 20237:00 amRNSUnaudited Preliminary Results
18th May 20237:00 amRNSNotice of Results
17th May 20238:56 amRNSHolding(s) in Company
27th Apr 20238:18 amRNSHolding(s) in Company
6th Apr 20234:17 pmRNSShare Purchase by Senior Independent NED
3rd Apr 20237:00 amRNSNew Scientific Advisory Board
28th Mar 20232:23 pmRNSDirector/PDMR Shareholding
23rd Mar 20237:00 amRNSChange of adviser
13th Mar 20237:00 amRNSReNeuron to present at Advanced Therapies 2023
9th Mar 20234:03 pmRNSHolding(s) in Company
3rd Mar 20239:37 amRNSShare Purchase by Chief Financial Officer
1st Mar 20237:01 amRNSBlock listing application
1st Mar 20237:00 amRNSBlock Listing Review & Total Voting Rights
24th Feb 202311:20 amRNSDirector Share Purchases
15th Feb 20237:00 amRNSGrant of Options
30th Jan 20234:38 pmRNSDirector/PDMR Shareholding
27th Jan 202311:05 amRNSSecond Price Monitoring Extn
27th Jan 202311:00 amRNSPrice Monitoring Extension
24th Jan 202310:55 amRNSShare Purchase by Chief Financial Officer
23rd Jan 20233:04 pmRNSShare Purchase by Executive Chairman
19th Jan 20237:00 amRNSCompany restructuring update
3rd Jan 20237:02 amRNSTotal Voting Rights
3rd Jan 20237:00 amRNSDirectorate Change
12th Dec 20222:31 pmRNSHolding(s) in Company
8th Dec 20227:06 amRNSPositive iPSC data presented at conference
2nd Dec 20224:40 pmRNSSecond Price Monitoring Extn
2nd Dec 20224:35 pmRNSPrice Monitoring Extension
2nd Dec 20222:00 pmRNSPrice Monitoring Extension
2nd Dec 20227:00 amRNSInterim Results
7th Oct 20227:00 amRNSPositive Exosome data presented at US conference
22nd Sep 20227:00 amRNSReNeuron to present new data at Exosome conference
14th Sep 20227:00 amRNSDirectorate and Executive Changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.